Big Pharma Has Spent Nearly $150 Billion On M&A (So Far) In 2025
In this week's edition of InnovationRx, we look at the biotech deal frenzy, Recursion's incoming CEO, the infant formula botulism outbreak, and more.
(Forbes, 2025-11-19T17:56:59Z)